Consolidated Statements of Stockholders’ Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)
Beginning balance (in shares) at Mar. 31, 2020		39,526,299
Beginning balance at Mar. 31, 2020	$ 61,558	$ 0	$ 820,257	$ (758,644)	$ (55)
Increase (Decrease) in Shareholders' Equity (Deficit)
Shares issued upon settlement of restricted stock units (in shares)		187,741
Shares sold in connection with at-the-market offering, net of brokerage fees and offering expenses (in shares)		29,663,527
Shares sold in connection with at-the-market offering, net of brokerage fees and offering expenses	89,231	$ 1	89,230
Stock-based compensation expense	4,492		4,492
Capital contribution received from Roivant Sciences, Inc.	121		121
Foreign currency translation adjustment	390				390
Net loss	(32,425)			(32,425)
Ending balance (in shares) at Mar. 31, 2021		69,377,567
Ending balance at Mar. 31, 2021	123,367	$ 1	914,100	(791,069)	335
Increase (Decrease) in Shareholders' Equity (Deficit)
Shares issued upon settlement of restricted stock units (in shares)		320,368
Shares sold in connection with at-the-market offering, net of brokerage fees and offering expenses (in shares)		739,445
Shares sold in connection with at-the-market offering, net of brokerage fees and offering expenses	1,441		1,441
Stock-based compensation expense	7,425		7,425
Shares issued upon exercise of pre-funded warrants (in shares)		3,301,998
Foreign currency translation adjustment	2				2
Net loss	(71,887)			(71,887)
Ending balance (in shares) at Mar. 31, 2022		73,739,378
Ending balance at Mar. 31, 2022	$ 60,348	$ 1	$ 922,966	$ (862,956)	$ 337